Payment overview · 2025
General Payments
$425.66
21 reported records · 16 companies
Healthcare provider profile · identity verified
Ryan D Crouch, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · GRAND ISLAND, NE · NPI 1790724201
Verified facts
What the public records show
CMS Open Payments records show Ryan D Crouch, D.O. received $425.66 in general payments during 2025 across 21 reported records.
Mallinckrodt Hospital Products Inc. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $98.38 | 23.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.47 | 8.8% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.45 | 8.8% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $33.07 | 7.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.61 | 6.7% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.50 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.77 | 4.9% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $20.60 | 4.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.39 | 4.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.47 | 3.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.21 | 3.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.10 | 3.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.14 | 3.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.88 | 3.5% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $13.91 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.71 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $425.66 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $98.38 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.47 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.61 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
152 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 563 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 530 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 89 |
| Potassium Chloride | Potassium Chloride | 445 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 422 | 108 |
| Simvastatin | Simvastatin | 364 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 322 | 76 |
| Metformin Hcl | Metformin Hcl | 314 | 71 |
| Allopurinol | Allopurinol | 299 | 63 |
| Omeprazole | Omeprazole | 280 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 276 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 261 | 58 |
| Furosemide | Furosemide | 255 | 54 |
| Sertraline Hcl | Sertraline Hcl | 253 | 46 |
| Gabapentin | Gabapentin | 243 | 52 |
| Lisinopril | Lisinopril | 237 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 49 |
| Tramadol Hcl | Tramadol Hcl | 157 | 50 |
| Eliquis | Apixaban | 152 | 25 |
| Meloxicam | Meloxicam | 147 | 36 |
| Montelukast Sodium | Montelukast Sodium | 138 | 31 |
| Warfarin Sodium | Warfarin Sodium | 136 | 22 |
| Carvedilol | Carvedilol | 127 | 22 |
| Xarelto | Rivaroxaban | 127 | 18 |
| Donepezil Hcl | Donepezil Hcl | 126 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 20 |
| Ozempic | Semaglutide | 116 | 16 |
| Alendronate Sodium | Alendronate Sodium | 113 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 23 |
| Alprazolam | Alprazolam | 109 | 27 |
| Jardiance | Empagliflozin | 108 | 16 |
| Atenolol | Atenolol | 101 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 11 |
| Trazodone Hcl | Trazodone Hcl | 88 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 86 | 17 |
| Chlorthalidone | Chlorthalidone | 83 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 83 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 12 |
| Glipizide Er | Glipizide | 70 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 15 |
| Buspirone Hcl | Buspirone Hcl | 67 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 17 |
| Lorazepam | Lorazepam | 62 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 16 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Sucralfate | Sucralfate | 60 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Synthroid | Levothyroxine Sodium | 55 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 11 |
| Prednisone | Prednisone | 53 | 29 |
| Famotidine | Famotidine | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Spironolactone | Spironolactone | 51 | 18 |
| Dutasteride | Dutasteride | 50 | suppressed |
| Glipizide | Glipizide | 50 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Torsemide | Torsemide | 46 | 11 |
| Finasteride | Finasteride | 44 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 20 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | suppressed |
| Zaleplon | Zaleplon | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 13 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Cefdinir | Cefdinir | 36 | 31 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 32 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 15 |
| Pregabalin | Pregabalin | 29 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 11 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 16 |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 13 |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Topiramate | Topiramate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Auryxia | Ferric Citrate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $425.66 · 21 records | Mallinckrodt Hospital Products Inc. | ABRYSVO, ACTHAR, BREZTRI, COMIRNATY, CRYSVITA, Cologuard Collection Kit, Fabhalta, GVOKE HYPOPEN, Kerendia, MOUNJARO, PREVNAR 20, REXULTI, SMARTVEST, SYMPLICITY G3, TRINTELLIX, VOQUEZNA, Vanrafia | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error